Highlight
- Mismatch repair deficiency (dMMR) in colorectal cancer (CRC) induces endoplasmic reticulum stress and DR5-mediated apoptosis.
- A DR5/Ligase 3 (Lig3) feedback loop promotes continual apoptosis and release of immunogenic extrachromosomal circular DNA (eccDNA).
- This feedback sustains immune activation and is critical for the efficacy of immune checkpoint inhibitor (ICI) therapy in dMMR CRC models.
- Clinical data show that higher DR5 and LIG3 expression correlate with improved ICI responsiveness in CRC patients.
Study Background
Colorectal cancer is a leading cause of cancer morbidity and mortality worldwide, with substantial therapeutic challenges. A subset of CRC exhibits deficient DNA mismatch repair (dMMR) leading to microsatellite instability (MSI), a molecular phenotype characterized by increased mutation burden. dMMR/MSI tumors have been recognized as inherently immunogenic, which underlies their relatively better response rates to immune checkpoint inhibitors (ICIs) such as PD-1 blockade. However, a sizeable number of dMMR/MSI CRC patients either fail to respond initially or develop resistance to immunotherapy, underscoring the incomplete understanding of the molecular factors governing tumor immunogenicity and ICI responsiveness. Delineating the mechanistic basis of dMMR-associated antitumor immunity is crucial for improving therapeutic outcomes and extending benefits to broader patient populations.
Study Design
Hao et al. employed a comprehensive experimental framework integrating syngeneic transplant tumor mouse models, immune cell co-culture assays, and air-liquid interface (ALI) cultures of tumor-derived organoids to dissect the cellular and molecular pathways linking dMMR to antitumor immunity. Genetic modulation of Mlh1, a DNA mismatch repair gene, was used to induce dMMR in murine colorectal cancer cells. Subsequent analyses investigated the cellular stress responses, apoptosis pathways, and immune cell activation in vitro and in vivo. Parallel interrogation of transcriptomic databases from CRC patients treated with ICIs allowed correlation of DR5 and LIG3 expression with clinical response to immunotherapy. This multifaceted approach enabled mechanistic insights bridging preclinical models with patient outcomes.
Key Findings
The study revealed that inactivation of the Mlh1 gene in colorectal tumors induces marked endoplasmic reticulum (ER) stress, which triggers apoptosis mediated by death receptor 5 (DR5). This apoptotic process was found not to be a terminal event but is sustained by a positive feedback loop involving nuclear DNA Ligase 3 (Lig3), which mediates the production and release of extrachromosomal circular DNA (eccDNA) from apoptotic cells. Released eccDNA acted as a potent immunogenic signal, activating immune cells and perpetuating antitumor immune responses within the tumor microenvironment.
This DR5/Lig3 amplification loop was demonstrated to be vital for maintaining immune engagement against Mlh1-deficient tumors. Disruption of this feedback significantly compromised immune activation and diminished the response to ICI therapy in mouse models. Importantly, clinical transcriptomic data analysis from CRC patients undergoing ICI therapy corroborated this mechanistic model; higher tumor expression levels of DR5 and LIG3 were associated with more favorable therapeutic responses.
Altogether, these findings establish a novel mechanistic link between mismatch repair deficiency, apoptotic signaling, and immune stimulation in colorectal cancer. The data suggest that the DR5/Lig3-eccDNA axis acts as an amplifier of immunogenic cell death, thereby enhancing tumor susceptibility to immunotherapy.
Expert Commentary
This study delineates a compelling molecular pathway that broadens our understanding of dMMR-driven immunogenicity beyond neoantigen load and mutation burden paradigms. By implicating DR5-mediated apoptosis and Lig3-dependent eccDNA generation as key immunostimulatory events, the work provides new targets for therapeutic modulation to potentiate immune responses in CRC and possibly other cancer types with differing MMR status.
Despite the robust preclinical validation and correlation with patient data, translation into clinical practice will require further confirmation of these pathways in diverse clinical cohorts and exploration of strategies to enhance or mimic this feedback loop. Moreover, the complexity of immune escape mechanisms in non-responsive dMMR tumors remains to be fully elucidated.
Conclusion
Hao et al. have identified a novel DR5/Lig3-mediated feedback loop that underpins the sustained immunogenicity of mismatch repair-deficient colorectal cancers. This molecular mechanism enhances apoptotic signaling and immune cell activation through the generation of immunogenic eccDNA. The findings provide a biologically plausible explanation for the variable response to immune checkpoint inhibitors observed in dMMR/MSI colorectal cancer patients and highlight potential therapeutic targets to improve outcomes. Further investigation into this pathway may yield novel biomarkers and combinatorial strategies to overcome resistance and extend immunotherapy benefits.
Funding and Clinical Trials
Details on study funding and related clinical trial registrations were not provided in the original publication abstract. Future clinical validation studies will be essential for translational advancement.
References
1. Hao S, Sato Y, Battaglin F, et al. A DR5/Ligase 3-mediated feedback loop perpetuates immunogenicity in mismatch repair deficient colorectal cancer. Gastroenterology. 2026 Jul 16. PMID: 42462829.
2. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413.
3. Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016 Oct;22(10):1342-1350.
4. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer. J Clin Oncol. 2017;35(15):1857-1865.
